AR
GSK icon

Advisory Research’s GSK GSK Stock Holding History

Advisory Research’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.3M Sell
204,282
-119,556
-37% -$6.48M 1.39% 27
2025
Q4 		$15.9M Buy
323,838
+7,074
+2% +$330K 2% 19
2025
Q3 		$13.7M Buy
316,764
+76,343
+32% +$2.98M 1.8% 20
2025
Q2 		$9.23M Buy
240,421
+13,172
+6% +$503K 1.42% 23
2025
Q1 		$8.8M Sell
227,249
-14,725
-6% -$539K 1.55% 23
2024
Q4 		$8.18M Sell
241,974
-20,103
-8% -$724K 1.36% 25
2024
Q3 		$10.7M Sell
262,077
-5,842
-2% -$239K 1.9% 19
2024
Q2 		$10.3M Buy
267,919
+143,346
+115% +$6.03M 1.94% 16
2024
Q1 		$5.34M Sell
124,573
-7,367
-6% -$304K 1.06% 31
2023
Q4 		$4.89M Buy
131,940
+6,099
+5% +$219K 0.75% 33
2023
Q3 		$4.56M Buy
125,841
+115,026
+1,064% +$4.08M 0.63% 34
2023
Q2 		$385K Buy
10,815
+2,418
+29% +$86.7K 0.05% 338
2023
Q1 		$299K Buy
+8,397
New +$294K 0.05% 292
2015
Q1 		– Sell
-11,332
Closed -$605K – 342
2014
Q4 		$605K Sell
11,332
-1,808
-14% -$101K 0.01% 293
2014
Q3 		$755K Buy
13,140
+1,236
+10% +$75.8K 0.01% 277
2014
Q2 		$796K Sell
11,904
-1,488
-11% -$101K 0.01% 270
2014
Q1 		$894K Buy
13,392
+560
+4% +$37.9K 0.01% 256
2013
Q4 		$856K Sell
12,832
-5,384
-30% -$349K 0.01% 253
2013
Q3 		$1.14M Sell
18,216
-4,792
-21% -$308K 0.01% 233
2013
Q2 		$1.44M Buy
+23,008
New +$1.46M 0.02% 218

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Advisory Research's GSK Position: Q1 2026 in Review

Advisory Research reduced its GSK (GSK) stake by 37% in Q1 2026, selling an estimated $6.48M and leaving 204,282 shares worth $11.3M. The position accounts for 1.39% of the portfolio, ranked #27.

Advisory Research first reported a position in GSK in Q2 2013 and has held it in 20 quarters since. The position peaked at $15.9M in Q4 2025. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Advisory Research held 204,282 shares of GSK worth $11.3M as of Q1 2026.
  • Advisory Research sold 119,556 GSK shares in Q1 2026, an estimated $6.48M.
  • GSK made up 1.39% of Advisory Research's portfolio in Q1 2026, its #27 holding.
  • Advisory Research first reported a position in GSK in Q2 2013 and has held it in 20 quarters since.
  • Advisory Research's GSK position peaked at $15.9M in Q4 2025.
  • 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Advisory Research's 13F filing for Q1 2026, filed 14 May 2026.